Related Experiment Video
Updated: Aug 22, 2026

Simultaneous Brightfield, Fluorescence, and Optical Coherence Tomographic Imaging of Contracting Cardiac Trabeculae Ex Vivo
Published on: October 2, 2021
Kawasaki disease with severe cardiac sequelae: lessons from recent New Zealand experience
1Paediatric Cardiology, Green Lane Hospital, Auckland 1030, New Zealand. nigelw@adhb.got.nz
Insights
Delayed diagnosis of Kawasaki disease (KD) in children increases cardiac risks. Early treatment with intravenous immunoglobulin (IVIG) is crucial for preventing severe coronary artery complications and improving outcomes.
Area of Science:
- Pediatrics
- Cardiology
- Immunology
Background:
- Kawasaki disease (KD) is a significant cause of acquired heart disease in children.
- Intravenous immunoglobulin (IVIG) is the standard treatment to prevent coronary artery aneurysms.
- Timely administration of IVIG (within 8-10 days of onset) is critical for efficacy.
Purpose of the Study:
- To review recent cases of Kawasaki disease (KD) with severe cardiac complications in New Zealand.
- To highlight the impact of diagnostic delays on treatment outcomes and patient prognosis.
Main Methods:
- Retrospective analysis of six pediatric cases of KD with significant coronary artery sequelae.
- Review of clinical course, diagnostic criteria, laboratory results, and cardiac findings.
Main Results:
- Three of six children experienced diagnostic delays, impacting treatment.
- All six patients exhibited significant coronary artery involvement, including aneurysms and thrombi.
- Three children died due to cardiac complications, including aneurysm rupture and coronary artery obstruction.
Conclusions:
- Kawasaki disease continues to pose a substantial risk of mortality and morbidity in children.
- Diagnostic delays beyond 8 days significantly diminish the effectiveness of IVIG therapy.
- Further epidemiological studies are needed to understand KD prevalence in New Zealand.
Objectives:
To review recent cases of Kawasaki disease (KD) with significant cardiac sequelae in New Zealand. It is known that intravenous immunoglobulin (IVIG) reduces the risk of coronary artery aneurysm formation if given within 8-10 days of onset of KD.
Methods:
Retrospective review of medical course, criteria for KD, laboratory and cardiac findings for six children identified with KD and significant coronary artery sequelae.
Results:
There was delay in diagnosis of KD in three of the six children. Three cases were atypical by extremes of age (2 months, 10 years, 14 years). By definition all six children had significant coronary artery involvement. One patient had a thrombus detected in a coronary aneurysm 3 weeks after KD. One patient underwent coronary artery bypass grafting for unstable angina 2 years after KD. One patient developed coronary artery aneurysms after an initial 'toxic shock' type illness evolving to KD. Three patients died, one due to rupture of a coronary artery aneurysm, two from rapid early coronary artery obstruction occurring at three and 4 months after initial KD.
Conclusions:
Kawasaki disease remains an important cause of mortality and morbidity for children. Diagnostic delay beyond 8 days reduces the chances of successful IVIG therapy in KD. Current studies supported by the Paediatric Surveillance Unit should establish the epidemiology of KD in New Zealand.
Related Concept Videos
Rheumatic Heart Disease III: Medical Management
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Rheumatic Heart Disease IV: Nursing Management
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease I: Introduction
Myocarditis III: Medical Management